ABSTRACT The contribution of vagal mechanisms to exercise-induced asthma has been studied in 10 adult asthmatic patients using the anticholinergic drug ipratropium bromide. Exercise tests were performed for eight minutes on a cycle ergometer and each individual's tests were standardised by matching oxygen uptake. Two tests were done on each of three study days, the first being without previous medication, and the second preceded by inhalation of ipratropium bromide, 0-1, or 1 mg or saline placebo given 90 minutes beforehand. The mean falls in FEV, and PEFR after the initial tests were very similar on the three study days. The mean falls in FEV, after the second test were 22-3%, 1955%, and 12-5% with placebo, 0*1 mg, and 1 mg ipratropium bromide respectively.
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Only the higher dose was significantly better than placebo. The results were also analysed using a protection index to compare the first and second tests each day and 1 mg ipratropium bromide was significantly better than both 0-1 mg and placebo. Similar results were obtained using PEFR. Equal bronchodilatation was produced by the two doses of drug. We conclude that conventional doses of anticholinergic drugs are not effective in preventing exercise-induced asthma, while large doses may do so in the same group of subjects.
There is now considerable evidence that the vagus nerve is important in modifying the response to various forms of airway challenge in asthmatic individuals. In man, anticholinergic drugs have been reported to reduce the bronchial response to antigen challenge' 2 as well as to agents which are thought to stimulate airway irritant receptors directly, such as citric acid, cold air, and dust. 3 The ability of anticholinergic drugs to prevent exercise-induced asthma (EIA) has been debated since Jones and his co-workers4 demonstrated that atropine inhibited it partially in four out of six children. Subsequent studies using atropine have given conflicting results5-9 but have shown some protection from EIA in a proportion of subjects. Tinkelman et al'0 suggested that the doses of atropine which had previously been used were inadequate and reported suppression of EIA in 17 of 18 children using large doses of inhaled atropine.
Ipratropium bromide (IB) is a newer anticholinergic drug which is a quarternary tropane alkaloid derivative of atropine. It has several advantages over atropine sulphate, particularly when used in moderately high doses. It does not cross the blood-brain barrier, has very little antihistaminic activity, is longer-acting, and its relative potency on bronchial smooth muscle is greater than on other target organs such as salivary glands." 12 Several reports have failed to show any benefit in EIA from standard bronchodilator doses of 0 04-0-08 mg IB,"-'5 although larger doses have been effective in about half the subjects studied.'16 ' Much published work has not separated the effect of bronchodilatation from specific antagonism of EIA. Not only can bronchodilatation alter airway reactivity"8 but failure to measure it before exercise challenge can produce an incorrect assessment of post-exertional bronchoconstriction if reference is made only to a pre-drug baseline. We have attempted to overcome these problems in studying the effects of 0-1 mg and I mg IB compared with placebo in a group of adults with ETA.
Subjects and methods
Four men and six women, age range 21-48 years (mean 32 years), gave their informed consent to 680
Cholinergic blockade in the prevention of exercise-induced asthana the studv. All had reversible airflow obstruction and were known to have exercise-induced asthma (>15% fall in FEV1 after a standard eight minute exercise test). Eight of the subjects had positive immediate skin prick tests to common allergens. Three subjects used inhaled beclomethasone dipropionate regularly, which was continued throughout the study, and one subject took sodium cromoglycate which was discontinued 24 hours before each test. Bronchodilator drugs were not taken within 12 Cotes.22 Failure to achieve a reduction of >15% in either PEFR or FEV1 after the first, drug-free, exercise test at each visit resulted in the patient being asked to attend on another occasion and in this way it was hoped to minimize the effect of variation of EIA wiith time. The results have been expressed in terms of maximal % fall in PEFR or FEV1 from the initial values immediately before exercise ([b-a/b] x 100) where b is the value before exercise, and a is the minimum value after exercise. Statistical analysis has been carried out on Loge a/b using paired t tests for inter-treatment comparisons of the second test each day. The difference between the degree of EIA induced by the first and second exercise tests at each visit has also been compared for each treatment day. For this a "percent protection index"9 23 has been used by which the difference between the percentage fall in PEFR or FEV1 after test 1 and test 2 on each treatment day are expressed as a percentage of the fall after test 1. Using this method, a fall of 40% after test 1 followed by a fall of 10% after test 2 on the same day would represent 75 % protection. The degree of protection given by each treatment has been compared by t test. This method of analysis has been used in addition to the more straightforward comparison in order to minimise inter-day variations in EIA because of altered environmental conditions. All exercise tests were done in a laboratory at a temperature of 20-240C, but humidity was not controlled and it is assumed that this would vary less in three hours than over several days.
Results
The exercise performance in terms of mean oxygen uptake and minute ventilation is shown in table 1. There was no significant difference between these values for any of the six exercise tests on the three days of the study. The second exercise test, 90 minutes after drug administration gives a measure of the protective effect of treatment on EIA. This has been examined in two ways-firstly, with a comparison of the fall in FEV1 after placebo with the falls after each dose of IB, and secondly, by using the percentage protection index (see methods).
There was no significant difference between placebo and 01 mg IB in the fall in FEV1 after exercise (figure and table 3), but there was a significant difference between placebo and 1 mg IB (p=0 007). The difference between the two doses of IB was not significant (p=0 11).
Using the percentage protection index, shown at the foot of table 3, only the high dose of IB was significantly better than placebo (p=0-003). However, this dose was now also significantly better than the lower dose of IB (p=0 02).
Values for FEV1 only have been shown in the figure and table 3 . The results using PEFR were similar, the percentage protection figures for placebo, 0-1 mg IB and 1 mg IB being 22-0, 44-4 and 64-5% respectively. 
Discussion
Although the mechanisms of EIA remain largely unknown, much recent interest has centred on the vagus nerve. There is evidence that the vagus may be important in allergen-induced asthma in man,' 2 although this is still disputed.24 Evidence for vagal involvement has usually been sought by using the anticholinergic drugs atropine and, more recently, IB. Therc. have been a large number of studies on the effect of these agents on EIA, and, almost 20 years since the first study, the evidence, and its interpretation, are still conflicting. Early studies used atropine in doses of 0 007-0-03 mg/kg given parenterally,4-7 and although the investigators generally were not impressed, EIA was suppressed or abolished in nine out of 22 subjects studied. Simonsson and his coworkers8 found inhaled atropine effective in six out of nine subjects and subsequent studies have usually used this method of administration. Nevertheless, other workers found rather poor protection from EIA in both children25 and adults. 26 Tinkelman and his co-workers'0 suggested that most studies had used inadequate doses of atropine and found a good reduction in EIA in 17 of 18 children using 01 mg/kg of atropine (approximately four to five times greater than doses used previously). This study is difficult to interpret because the effect of bronchodilatation was not taken into account, and it differs considerably from other studies in the degree of protection afforded by atropine. Godfrey and Konig9 found significant protection in seven children using atropine methonitrate aerosol, although only four of the individuals responded.
The effect of the newer anticholinergic drug IB was first reported in 197213 and studies using 004-0008 mg, the usual amount required when the drug is used as a bronchodilator, have shown little effect on EIA,13-'5 with one exception.27
Larger doses of IB have been used with more consistent effects. McFadden and his co-workers '6 gave enough IB by inhalation to block the bronchoconstrictor response to 1 % methacholine challenge, and found inhibition of EIA in five out of 12 subjects, and Thomson and his colleagues17 gave 2 mg IB and found that eight out of 13 subjects were protected.
Thus there has been considerable variation in the reported response to cholinergic blockade. Some of this relates to dosage and method of administration, and some to thc fact that anticholinergic drugs are bronchodilators with a rather slow onset of action and time should be allowed for a stable higher level of lung function to be reached before any interpretation of a post-exercise reduction can be made. Most studies have used small numbers of subjects and, if the degree of vagal importance in EIA is variable between individuals, chance selection could have accounted for some of the anomalies described between different studies. We This interpretation presupposes that lB was acting only as an anticholinergic drug in both the doses used, and this is probably the case in view of its known pharmacology." 12 Another possible explanation would be that 1 mg IB had a greater bronchodilator effect than 01 mg IB, but that we failed to observe this by measuring only PEFR and FEV,. An increase in the size of large central airways could change airway reactivity and might also alter heat exchange across them (see below). Since PEFR and FEV, predominantly reflect large airway calibre, although not being as sensitive as plethysmographic measurements of airways resistance, we think it unlikely that large differences occurred of which we were unaware. There have, however, been no detailed reports of the bronchodilator effects of two doses of IB similar to those we used.
These findings suggest that in half our group of subjects, vagal reflexes were important in mediating EIA. It is difficult to know whether different mechanisms were operating in the other five subjects, or whether we failed to achieve adequate cholinergic blockade even with 1 mg IB. Thomson and his co-workers'7 only found eight subjects out of 13 whose EIA was blocked by twice this dose, and it would appear that present techniques using cholinergic blockade will only show vagal mechanisms to be important in half to two-thirds of subjects with EIA.
The trigger for initiating a vagal reflex when one is present is also uncertain. Recent work has suggested that the primary event in EIA may be cooling of the airway mucosa subsequent upon exercise hyperventilation.28 29 
